Exelixis
Presença
Executivos
Veja o organograma con seus 27 executivos principais
Biografias mais buscadas da Exelixis
- Michael Morrissey, Director, Chief Executive Officer and President
- Bob Oliver, Director
- Jack Wyszomierski, Director
Recentes movimentos de executivos em Exelixis
- Gail Eckhard, ingressou na Companhia como Director (Notícia publicada em 8 de janeiro de 2024).
- Mary Beckerle, ingressou na Companhia como Director (Notícia publicada em 8 de janeiro de 2024).
- Amy Peterson, ingressou na Companhia como Executive Vice President, Product Development & Medical Affairs and Chief Medical Officer (Notícia publicada em 24 de agosto de 2023).
Criar um alerta
para seguir os movimentos de executivos da Exelixis.
Biotecnologia
Exelixis possui 2.276 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e Adaptive Phage Therapeutics (Estados Unidos).
Popular M&A news in Biotecnologia
- Histogen has filed for bankruptcy protection (publicado em 19 de abril de 2024).
- Bruker has announced the acquisition of NanoString Technologies (publicado em 18 de abril de 2024).
- Vertex Pharmaceuticals has announced the acquisition of Alpine Immune Sciences (publicado em 16 de abril de 2024).
Outros contatos sugeridos na indústria do Biotecnologia
Notícias
Últimos comunicados de imprensa de Exelixis
- Exelixis to Release Second Quarter 2022 Financial Results on Tuesday, August 9, 2022 | Exelixis, Inc.
- Exelixis Announces Cabozantinib in Combination with Nivolumab and Ipilimumab Significantly Improved Progression-Free Survival in Phase 3 COSMIC-313 Pivotal Trial in Patients with Previously Untreated Advanced Kidney Cancer | Exelixis, Inc.
- Exelixis and Ryvu Therapeutics Establish Exclusive License Agreement to Develop Novel STING Agonist-Based Targeted Cancer Therapies | Exelixis, Inc.
- Exelixis to Webcast Fireside Chat as Part of the William Blair Biotech Focus Conference | Exelixis, Inc.
- Exelixis Announces Initiation of the STELLAR-303 Phase 3 Pivotal Trial Evaluating XL092 in Patients with Metastatic Colorectal Cancer | Exelixis, Inc.
- Exelixis and BioInvent Establish Exclusive Option and License Agreement to Develop Novel Antibody-Based Immuno-Oncology Therapies | Exelixis, Inc.
- Exelixis To Webcast Fireside Chats as Part of Investor Conferences in June | Exelixis, Inc.
- Exelixis Announces Detailed Results from Urothelial Carcinoma and Non-Small Cell Lung Cancer Cohorts of the COSMIC-021 Trial at ASCO 2022 | Exelixis, Inc.
- Exelixis Announces Results from Phase 2 Trial of Cabozantinib in Combination with Pembrolizumab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma at ASCO 2022 | Exelixis, Inc.
- Exelixis Announces First Quarter 2022 Financial Results and Provides Corporate Update | Exelixis, Inc.
- View more press releases Close
Redes sociais sobre Exelixis
- Exelixis na Wikipedia, Google News e Yahoo Finance
- Exelixis na LinkedIn, Twitter e YouTube
Entrar em contato
Contate seus executivos por e-mail agora, incluindo Michael Morrissey 
Ligue para a Exelixis em +1 650...
